Efficacy of Yavanishadavadi Vati with Drakhsavaleha as an adjunct therapy in the management of Rajyakshma ( Multi Drug Resistant (MDR) Pulmonary Tuberculosis) - An open label randomized controlled trial - NA

Institute of Teaching and Research in Ayurveda Jamnagar0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年8月21日

试验速览

暂无简介。

•1.Patients willing to comply with all study procedures and availability for the duration of the study.
•2.Patients having Rifampsin resistance or Isoniazid resistance.
•3.Patients with primary and acquired resistance to MTB.

•1.Patients having uncontrolled cardiac, renal, hepatic disease, HIV-AIDS, malignancy, cancer and other associated lung disease.
•2.Pregnant and lactating women.
•3.Patients who are getting first line (primary DS PTB) Anti tubercular treatment.
•4.MDR PTB patients whose acute illness required intensive care.
•5.Patient who are intolerated to ATD regimen
•6.Extra pulmonary PTB patients will be excluded
•7.Patients having both Rifampsin and Isoniazid or any other drug resistance from the ATD regimen.
•8.Patients with longer (18-24 months) ATD regimen.

发起方

Institute of Teaching and Research in Ayurveda Jamnagar